Myriad Genetics Q3 net loss widens 60% year over year to $43.9 million; Q3 revenue falls year over year to $202.7 million

Bitget2026/11/04 21:34

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Myriad Genetics’ third-quarter 2026 net loss widened 60% year-over-year to $43.9 million.
Revenue fell year-over-year to $202.7 million, while operating expenses rose 6% to $177.6 million.
Agreed to sell Prenatal Health to Labcorp for $210 million plus inventory value, with closing expected by early 2027.
Raised the midpoint of full-year 2026 revenue guidance to a range of $780 million to $790 million, reflecting quarterly results and current trends.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Myriad Genetics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611041605PRIMZONEFULLFEED9870515) on November 04, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

According to reports, the trading firm JonesTrading is marketing up to $500 million worth of stock shares on behalf of some investors, at a 3% to 5% premium over the IPO issue price. This indicates that investors are already transferring their anticipated IPO allotted shares before the IPO is officially issued.

华尔街见闻•2026/11/10 23:03